Ultragenyx Pharmaceutical Inc., is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases, announced results ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction endpoints, eroding its key growth narrative. RARE's financials are stressed, with ...

"We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant ...

Setrusumab did not meet primary fracture endpoints in the ORBIT and COSMIC trials but significantly improved bone mineral density in patients with osteogenesis imperfecta. Topline data were announced ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...

After 20 years playing around the world, the group had two UK gigs cancelled this year after protests from activists. It’s made them feel targeted for who they are, the band say Josh Breslaw was ...

Forever Young won't be young forever but there's no shortage of talented and slightly younger Japanese dirt specialists who look capable of following the Breeders' Cup Classic (G1) winner onto the ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

But the controversial 2023 Jonny Bairstow stumping at Lords continues to ignite Ashes tensions with a senior member of England’s Barmy Army delivering a devastating critique of Australian ...

Rei is the Deputy Lead for GameRant's Anime Team from Kashmir, situated in Beirut. He's an avid fan of anime and manga. Rei grew up watching anime and had a knack for writing ever since he was a kid, ...

We need to be upfront with you. The Reader is free. Producing it isn’t. And without your support, we can't continue. So we need you to chip in, even if it’s just a few bucks. The average donation is ...

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its ...